Eisai contributes to the science of cancer medicine at ASCO 2022 - Benzinga

Eisai contributes to the science of cancer medicine at ASCO 2022 – Benzinga


Farletuzumab Eteribulin Data (MORAb-202) Demonstration of Eisai’s advanced chemical capabilities and commitment to identifying new approaches to cancer treatment to improve patient outcomes

Presentations containing post-hoc analyzes from the LEAP clinical program (LEnvatinib and pembrolizumab) may provide new information on the treatment of patients with advanced
Renal cell carcinoma and advanced endometrial carcinoma

TOKYO, May 27, 2022 – (JCN Newswire) – Eisai Co., Ltd. today announced a presentation of research into various types of cancer from its oncology portfolio during the annual meeting of the American Society for Clinical Oncology (ASCO) in 2022 (# ASCO22), which takes place virtually and in person in Chicago from June 3 to 7. Notable presentations include a poster discussion of safety and efficacy data (NCT03386942; Abstract: # 5513) from the expansion of a platinum-resistant ovarian cancer cohort in a Phase 1 study evaluating an antibody-drug conjugate (ADC) jointly developed by Eisai and Bristol Myers Squibb. United States), farletuzumab ecteribulin (MORAb-202), as well as a poster presentation with dose optimization results for farletuzumab ecteribulin (NCT03386942; Abstract: # 3090).

“Analysis of the safety and efficacy of farletuzumab ecteribulin in platinum-resistant ovarian cancer suggests that antibody-drug conjugates may represent a promising therapeutic strategy for these patients with limited treatment options,” said Dr. Takashi Owa, President of Oncology Business Group at Eisai. “The first Eisai antibody-drug conjugate combines our internally developed anti-folate alpha receptor antibody and our anti-cancer agent eribulin with a cleavable linker enzyme, illustrating our commitment to build on our drugs to improve cancer care for more patients.”

A new study of the LEAP clinical program (LEnvatinib And Pembrolizumab) evaluating lenvatinib (LENVIMA) plus pembrolizumab (KEYTRUDA), an anti-PD-1 therapy from Merck & Co., Inc., Rahway, NJ, USA, includes subgroup analyzes from a pivotal phase study 3 CLEAR (Study 307) / KEYNOTE-581 combination evaluation in patients with advanced renal cell carcinoma (RCC) and Phase 3 study Study 309 / KEYNOTE-775 evaluation combination in patients with advanced endometrial cancer (EC). The poster discussion will evaluate the impact of follow-up therapies in patients with advanced RCC using the combination (NCT02811861; Abstract: # 4514); while the poster presentation will discuss the efficacy of another line of therapy after lenvatinib plus pembrolizumab treatment in advanced EC (NCT03517449; Abstract: # 5587).

“The combination of lenvatinib and pembrolizumab has helped expand the medical arsenal of treatment options for patients living with advanced renal cell carcinoma and advanced endometrial carcinoma worldwide,” said Richard C. Woodman, MD, Chief Clinical Officer, Oncology Business Group at Eisai. “Our data at ASCO 2022 demonstrate our commitment to continue exploring this combination through post-hoc analysis to provide healthcare professionals with the tools to help them make more informed decisions about their patients’ treatment.”

In March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada), through an affiliate, entered into strategic collaboration on global joint development and joint commercialization. lenvatinib, either alone or in combination with pembrolizumab. To date, more than 20 studies have been launched under the LEAP clinical program, which evaluates a combination of more than 10 different tumor types.

In June 2021, Eisai and Bristol Myers Squibb entered into an exclusive global strategic agreement to collaborate on the joint development and joint commercialization of farletuzumab ectyibulin, an folate receptor alpha (FRα) ADC. Eisai and Bristol Myers Squibb are currently investigating farletuzumab ecteribulin in FRα-positive solid tumors (including endometrial, ovarian, lung and breast cancer) in two studies: a phase 1 clinical study in Japan and a phase 1/2 clinical study in the United States.

This release discusses investigated compounds and research applications for FDA-approved products. It is not intended to communicate conclusions on efficacy and safety. There is no guarantee that any test compounds or trial uses of FDA-approved products will successfully complete clinical development or obtain FDA approval.

For more information, visit www.eisai.com/news/2022/pdf/enews202241pdf.pdf.

Media inquiries:
public relations department
Eisai Co., Ltd.
+ 81- (0) 3-3817-5120

Source: Eisai

Copyright 2022 JCN Newswire. All rights reserved.



Source link

Leave a Comment

Your email address will not be published.